James Edeerfield Management... Net Worth

The estimated Net Worth of James Edeerfield Management... is at least 13.7 百万$ dollars as of 25 June 2018. James Management owns over 114,034 units of Avadel Pharmaceuticals plc stock worth over 12,998,417$ and over the last 6 years James sold AVDL stock worth over 683,064$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James Management AVDL stock SEC Form 4 insiders trading

James has made over 1 trades of the Avadel Pharmaceuticals plc stock since 2018, according to the Form 4 filled with the SEC. Most recently James sold 114,034 units of AVDL stock worth 683,064$ on 25 June 2018.

The largest trade James's ever made was selling 114,034 units of Avadel Pharmaceuticals plc stock on 25 June 2018 worth over 683,064$. On average, James trades about 114,034 units every 0 days since 2018. As of 25 June 2018 James still owns at least 952,265 units of Avadel Pharmaceuticals plc stock.

You can see the complete history of James Management stock trades at the bottom of the page.

What's James Management's mailing address?

James's mailing address filed with the SEC is 780 3rd Ave, New York, NY 10017, USA.

Insiders trading at Avadel Pharmaceuticals plc

Over the last 8 years, insiders at Avadel Pharmaceuticals plc have traded over 7,791,038$ worth of Avadel Pharmaceuticals plc stock and bought 775,568 units worth 4,366,224$ . The most active insiders traders include Healthcare Master Fund Ltd ...、Kevin Broadfin Capital, Llc...、Naseem Amin. On average, Avadel Pharmaceuticals plc executives and independent directors trade stock every 43 days with the average trade being worth of 381,436$. The most recent stock trade was executed by Thomas S Mchugh on 16 January 2024, trading 2,000 units of AVDL stock currently worth 29,000$.

What does Avadel Pharmaceuticals plc do?

avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.

Complete history of James Management stock trades at Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc executives and stock owners

Avadel Pharmaceuticals plc executives and other stock owners filed with the SEC include:

• Gregory J. Divis Jr.,
  CEO & Director
• Dr. Jordan S. Dubow M.D.,
  Consultant
• Thomas S. McHugh,
  Sr. VP & CFO
• Angie Woods,
  VP of People & Culture
• Richard Kim,
  Chief Commercial Officer
• Dr. Jason M. Vaughn,
  Sr. VP of Technical Operations
• Steven G. Sullivan,
  VP of Sales & Marketing and Head of Commercial Operations
• Christian Kalita Pharm.D,
  Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
• Séverine Martin,
  Director of HR and Corp. Projects
• Mark W. Elrod,
  VP of Sales
• Gregory J. Davis,
  VP of Corp. and Bus. Devel.
• Phillandas T. Thompson,
  See Remarks
• Marcus W Elrod,
  See Remarks
• David Monteith,
  See Remarks
• Healthcare Master Fund Ltd ...,
  
• Craig R Stapleton,
  Director
• Guillaume Cerutti,
  Director
• Michael F Kanan,
  See Remarks
• Christophe Navarre,
  Director
• Francis Fildes,
  Director
• Stephen G. Sullivan,
  See Remarks
• Scott A. Macke,
  See Remarks
• David P Gusky,
  See Remarks
• Jason Vaughn,
  Sr. VP, Technical Operations
• Mark Anthony Mc Camish,
  Director
• Healthcare Master Fund Ltd ...,
  
• Peter J. Thornton,
  Director
• Naseem Amin,
  Director
• Gregory J. Davis,
  See Remarks
• Dhiren D'silva,
  See Remarks
• James Edeerfield Management...,
  
• Assche Benoit Van,
  Director
• Geoffrey Michael Glass,
  Director
• Linda Palczuk,
  Director
• Michael S Anderson,
  Chief Executive Officer
• Kevin Broadfin Capital, Llc...,
  
• Eric J Ende,
  Director
• Thomas S Mchugh,
  Chief Financial Officer
• Jordan Dubow,
  Chief Medical Officer
• Richard J Kim,
  Chief Commercial Officer
• Gregory J Divis,
  Chief Executive Officer
• Douglas J Williamson,
  Chief Medical Officer